Advertisement

Dolutegravir Approved to Treat HIV — Physician’s First Watch

Medical News |
August 14, 2013

Dolutegravir Approved to Treat HIV

By Kelly Young

The FDA has approved dolutegravir (Tivicay), an integrase strand transfer inhibitor, to treat HIV in both treatment-naive and treatment-experienced patients, the agency announced.

The once-daily pill is approved for use in adults, including those who've taken other integrase strand transfer inhibitors, and children ages 12 and over who've never taken another integrase strand transfer inhibitor.

Roughly 2500 adults with HIV participated in four clinical trials of dolutegravir. Regimens containing dolutegravir reduced viral loads as well as, or better than, regimens containing raltegravir (Isentress) or efavirenz, emtricitabine, and tenofovir (Atripla).

In his HIV and ID Observations blog, Paul Sax called the new drug an "extraordinarily promising antiviral agent." He added that "it's the end of a remarkable stretch of HIV drug development," with six other drugs approved since 2006. The availability of all of these agents, he writes, "means that pretty much anyone who takes their medications will achieve virologic suppression."

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement